Compare · DERM vs SLGL
DERM vs SLGL
Side-by-side comparison of Journey Medical Corporation (DERM) and Sol-Gel Technologies Ltd. (SLGL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DERM and SLGL operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- SLGL is the larger of the two at $184.2M, about 1.5x DERM ($123.9M).
- DERM has been more active in the news (4 items in the past 4 weeks vs 3 for SLGL).
- SLGL has more recent analyst coverage (9 ratings vs 7 for DERM).
- Company
- Journey Medical Corporation
- Sol-Gel Technologies Ltd.
- Price
- -
- -
- Market cap
- $123.9M
- $184.2M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2018
- News (4w)
- 4
- 3
- Recent ratings
- 7
- 9
Journey Medical Corporation
Journey Medical Corporation develops and commercializes pharmaceutical products for the treatment of dermatological conditions. It markets generic prescription drugs for dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products. Sol-Gel Technologies Ltd. has collaboration with Perrigo. The company was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
Latest DERM
- SEC Form 10-Q filed by Journey Medical Corporation
- Journey Medical Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Journey Medical Corporation Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
- Journey Medical Corporation to Announce Third Quarter 2026 Financial Results on November 12, 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by Journey Medical Corporation
- Journey Medical Corporation to Participate in September 2026 Investor Conferences
- Longeveron Appoints Nirav Jhaveri as Chief Financial Officer
- SEC Form 10-Q filed by Journey Medical Corporation
- Journey Medical Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Latest SLGL
- SEC Form 6-K filed by Sol-Gel Technologies Ltd.
- Sol-Gel Reports Third Quarter 2026 Financial Results and Provides Corporate Updates
- Amendment: SEC Form SCHEDULE 13G/A filed by Sol-Gel Technologies Ltd.
- Cantor Fitzgerald initiated coverage on Sol-Gel
- SEC Form 6-K filed by Sol-Gel Technologies Ltd.
- Sol-Gel Technologies to Host KOL Investor Day for SGT-610 on October 14, 2026
- SEC Form 6-K filed by Sol-Gel Technologies Ltd.
- SEC Form 6-K filed by Sol-Gel Technologies Ltd.
- Sol-Gel Technologies Announces Last Patient Last Visit in Pivotal Phase 3 Clinical Trial of SGT-610 in Gorlin Syndrome
- Large owner Opaleye Management Inc. bought $207,399 worth of Ordinary Shares (3,124 units at $66.39) (SEC Form 4)